EXECUTIVE LEADERSHIP
Meet Elektrofi’s executive leaders and biotech pioneers. This team is responsible for the company’s strategic direction, its operational oversight, and for enabling the company’s vision to reimagine the delivery of life saving and life changing medicines.
-
Chief Executive Officer
Chase Coffman is the Chief Executive Officer and co-founder of Elektrofi. Since the company’s inception in 2015, Chase has combined his deep expertise in technology and roots in science with his passion for solving challenges to change people’s lives.
His extensive background in fluid mechanics and microsystems helped form the foundation for Elektrofi’s ultra-high concentration microparticle platform technology. As an academic, Chase focused on paradigm-shifting space propulsion technologies for nanosatellites, related laser micromachining techniques, and electrohydrodynamic theories that have applications in a wide range of fields. This proven track record, coupled with his collaborative approach to co-creation, enables trusted relationships with Elektrofi’s partners and colleagues alike.
Prior to founding Elektrofi, he served as a Space Technology Research Fellow with National Aeronautics and Space Administration (NASA).
Chase holds a Ph.D. in Philosophy and a Master of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. He earned his Bachelor of Science in Aerospace Engineering from the University of Florida.
-
Chief Operating Officer
Joanne is a seasoned biotech executive with over 30 years of experience across large pharma and early-stage biotech in the areas of operations, leadership, product development, process development, clinical & commercial manufacturing, and supply chain. Over the course of her career, she has contributed to the licensure and commercialization of numerous medicines across different modalities and therapeutic areas. She has fostered high-performing, empowered individuals and teams and mutually beneficial partnerships with both internal and external stakeholders.
Before Elektrofi, Joanne most recently served as the Chief Technical Officer at Abata Therapeutics, a company developing Treg cell therapies for serious autoimmune and inflammatory diseases. Prior to Abata, she served as the Chief Technical Officer at Aerium Therapeutics, Inc. and as the Chief Operating Officer and interim CEO at Boston Pharmaceuticals. Previously, Joanne served as the Executive Vice President of Global Pharmaceutical Development and Operations at Celgene Corporation where she oversaw the company’s Product Development, Global Manufacturing Operations, Supply Chain, Engineering and Quality functions. Joanne also served in leadership positions at other pharmaceutical and biotech companies, including Shire, Abbott Laboratories, Amgen, and Genentech. She has served as a member of the Board of Directors of public biopharmaceutical companies, including Orchard Therapeutics and Astria Therapeutics.
Joanne holds a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.
-
Chief Technology Officer
Victoria Sluzky is the Chief Technology Officer (CTO) responsible for Elektrofi’s pharmaceutical development process including process development, formulation, analytics, and innovation. She will also oversee the company’s Chemical, Manufacturing, and Controls (CMC) groups, Regulatory, and related processes in support of advancing the Company’s clinical programs. As an executive leader, Victoria has guided analytical, formulation, and process development teams to transform the vision of research scientists into manufacturing processes and quality control systems that withstood rigorous regulatory and compliance requirements, enabling the availability of new therapies.
Specializing in quality, manufacturing, and pharmaceutical development of gene therapy and biologic therapeutics, Victoria brings more than 30 years of healthcare and biotechnology experience to Elektrofi, including 19 years of significant contributions to BioMarin Pharmaceutical, where she most recently served as Senior Vice President of Technical Development. Victoria earlier roles in biotechnology focused on leading analytical and formulation development groups at Onyx Pharmaceutical, COR Therapeutics, and Scios. Her strategic vision and contributions led to the approval of nine commercial products including Aldurazyme®, Brineura®, Integrilin®, Kuvan®, Naglazyme®, Palynziq®, Roctavian™, Vimizim®, and Voxzogo®.
Victoria holds a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology and a Bachelor of Science in Chemical Engineering from Stanford University. She serves as a Fellow of American Institute of Medical and Biological Engineers, a non-profit organization headquartered in Washington, D.C., representing the most accomplished individuals in the fields of medical and biological engineering.
FUNCTIONAL LEADERSHIP
Meet the people behind Elektrofi. These leaders and teams power our innovative technology, science, and processes.
-
Vice President, Drug Product Innovation
Paul Brown, Ph.D. leads the company’s Innovation team. In this role, he’s accountable for evolving and optimizing the company’s current technology platform and potential uses, while also exploring new methodologies and opportunities of impact. He is a physical chemist and one of the scientific co-founders of Elektrofi’s proprietary formulation technology platform. Paul plays a vital role in the company’s growth across drug product development, process scale-up, translation, and device selection.
Prior to joining Elektrofi, Paul worked at several research institutions, including the Massachusetts Institute of Technology, Oakridge National Laboratory, and the Rutherford Appleton Laboratory, where he authored 45 peer-reviewed papers in the fields of biology, materials science, chemical engineering, and physics. His proven expertise in interface and colloid science and its applications across pharmaceuticals, biotechnology, nanotechnology, and materials led to his developing 18 registered patents.
Paul holds a Ph.D. in Physical Chemistry and a Master in Chemistry from the University of Bristol.
-
Vice President, Head of Program Management and Strategy
Lyndon Charles is Vice President and Head of Program Management and Strategy, responsible for driving Elektrofi’s partnership programs and pipeline, and ensuring program goals are being met collaboratively, with efficiency, quality, and speed. He leverages his broad range of experience to enable a holistic view of our programs to prioritize activities, proactively manage challenges and find synergies, and actively pursue shared goals for developing and commercializing assets.
Lyndon is a biomedical engineer and scientist who is passionate about leading diverse teams to develop new technologies in the pursuit of solving complex biomedical problems.
Prior to joining Elektrofi, he served as a postdoctoral Research Scientist at the Massachusetts Institute of Technology, a Research Assistant at the University of Connecticut, and a National Science Foundation Research Scholar awardee at École Polytechnique Fédérale de Lausanne (EPFL). Across these roles, Lyndon managed cross functional teams and worked on highly collaborative academia-industry partnerships with companies such as Sanofi, BioTime, and Aruna BIO. Lyndon has authored 11 peer reviewed papers in the fields of drug delivery, regenerative engineering, and aging. His proven expertise in the development of novel drug delivery technologies and their applications across regenerative medicine has led to intellectual property supporting the commercialization of products and launching of biotech startups.
Lyndon holds Ph.D. in Biomedical Science, and a Bachelor of Science in Biomedical Engineering from the University of Connecticut.
-
Vice President, Pharmaceutical Development
Willow DiLuzio leads the company’s Pharmaceutical Development Team responsible for formulation development and process development for clinical development programs and for progressing Elektrofi’s formulation and process platform technology and understanding.
Willow has over 20 years of experience in protein and small molecule formulation development, drug product process development, aseptic drug product manufacturing, combination product development and manufacturing, definition of analytical and process control strategies, CMC program management, CMC regulatory strategy and CMC organizational design. Prior to joining Elektrofi, Willow was Vice President of Pharmaceutical Development and CMC Program Management at Sarepta where she was a key contributor to the development and regulatory approval of oligonucleotide and gene therapy products including Vyondys 53®, Amondys 45®, and Elevidys®.
Prior to Sarepta, Willow worked at Millennium/Takeda for over 13 years where she held roles of increasing responsibility and was the Global Vice President of Drug Product Development where she oversaw teams in the US and Japan responsible for drug product development and manufacturing, device and combination product development, and product innovation. While at Takeda, Willow advanced numerous clinical development candidates and was instrumental in the development and approval of monoclonal antibody products Entyvio® IV and Entyvio® SC and oral oncology product Ninlaro® and Willow also worked at DuPont Pharmaceuticals.
Willow holds a Ph.D. in Engineering from Harvard University and a Bachelor of Science in Chemical Engineering from The University of Massachusetts at Amherst.
-
Senior Vice President, Legal and Human Resources
Ben is an experienced and strategic leader with a proven track record of helping companies scale and innovate. As Senior Vice President, Ben leads Elektrofi’s legal and HR functions with a focus on protecting innovation, supporting business growth, mitigating risks, and ensuring compliance in a rapidly evolving landscape.
With a deep expertise in intellectual property and corporate law, Ben has been instrumental in helping companies build, manage, and enforce patent portfolios, and license patents and other technology. Ben has also helped numerous startup companies build and enhance the legal infrastructure necessary to support growth, and negotiate transformative agreements, whether by license, partnership, or M&A.
Ben has over two decades of experience working with companies at all stages of development. Prior to joining Elektrofi, Ben served as VP, Legal Affairs at Theseus Pharmaceuticals, General Counsel at Tremeau Pharmaceuticals, General Counsel at Finch Therapeutics, and Corporate Counsel at Moderna and Sunovion Pharmaceuticals. Ben began his career as a litigation associate at two national law firms, Holland & Knight and Fish & Richardson.
Ben holds a J.D. from Cornell Law School (cum laude) and a Bachelor of Arts in Chemistry and Anthropology from Vanderbilt University.
-
Vice President, Operations
Angela Hui leads the company’s lab operations and facilities teams, responsible for laboratory operations and facilities management to ensure the efficient and effective functioning of our scientific research and development efforts. She also oversees the company’s information technology systems.
She is an accomplished operations leader with proven experience designing lab spaces and management. Angela has significant expertise within the areas of lab operations oversight, facility design, and sample management. Prior to joining Elektrofi, Angela led a site team for SmartLabs and held roles of increasing responsibilities for 15 years at Amgen in R&D Lab operations. During this time, she supported its Discovery Research business focused on process optimization, cross-site alignment, and operational excellence.
Angela has a Bachelor of Science from Northeastern University. She is a board member of LabOps Unite Community, a global community of operations professionals, where she serves as vice chair and leads its mentorship program across the United States, Europe, and Canada.
-
Senior Vice President, Technical Operations
Jason Martin is Elektrofi's SVP, Head of Technical Operations responsible for Internal & External Manufacturing, Supply Chain, MS&T, Corporate Operations, Laboratory Operations, Facilities & Engineering, Environment Health & Safety, Security, and Information Security & Technology.
Jason is highly accomplished with over twenty-five years of progressive business and operations experience in the domestic and global biopharmaceutical industry. He is an enterprise leader with proven track record of executing successful strategic initiatives, startups, turnarounds, product launches, and oversight of manufacturing operations from early clinical phase through routine commercial supply. His passion is leveraging novel technologies to manufacture products that improve patients' health worldwide.
Prior to Elektrofi, Jason held various roles at Bristol Myers Squibb in the cell therapy division as VP Cell Therapy Operations Global Manufacturing Science & Technology, Global Head of Cell Therapy Network Strategy & Planning, and Site Head of Cell Therapy Manufacturing. While at BMS, he worked on Abecma® and Breyanzi® commercialization and four INDs for novel cell therapy clinical pipeline products.
Jason also held roles at Novartis as Americas Head of External Supply Operations Business Development & Product Launch and Director of Americas External Supply Quality Operations. While at Novartis, he worked on the commercial launch of 40 products including the first US FDA Approved Biosimilar Zarxio™ (filgrastim-sndz) and Glatopa®. He had quality oversight of 54 commercial products including Enoxaparin, Decitabine, Budesonide, & Cyclophosphamide manufactured at CDMOs globally and supplied to the Americas region.
Early in his career, Jason worked at Merck & Co., Inc. in various Technical Operations roles in both the small molecule and vaccine divisions. While at Merck, he supported the manufacturing of 40 sterile biological vaccines and pharmaceutical drug products. He worked extensively on development and commercialization of Gardasil®, RECOMBIVAX®, HEXAVAC® (via JV with Sanofi), and INVANZ®.
Jason has a M.ENG. Chemical Engineering (minor biotechnology) and B.S. Chemical Engineering (pre-medical) degrees from Lehigh University.
-
Senior Director, Formulation Development
Chaitanya Sudrik leads Elektrofi's Process Development team and is responsible for the ongoing development and scale-up of the company’s platform manufacturing process. Prior to leading this team, Chaitanya was responsible for developing platform formulation approaches that enable subcutaneous delivery of ultra-high concentration biologics.
Chaitanya is a respected thought leader, having authored and spoken at conferences on topics including protein stability, pre-formulation, and thermodynamics of protein-excipient interactions. He has authored several peer-reviewed articles on the topics of excipient-mediated protein stabilization, riboswitches, and optogenetics.
Prior to joining Elektrofi, Chaitanya conducted his post-doctoral training at the Molecular Engineering Laboratory at Massachusetts Institute of Technology where he conducted research on the development of high concentration protein formulations.
Chaitanya holds a Ph.D. in Chemical and Biological Engineering from Rensselaer Polytechnic Institute and a Bachelor of Science in Chemical Engineering from the Institute of Chemical Technology, Mumbai.
-
Executive Director, Analytical Development
Bernice Yeung leads the Analytical Development group at Elektrofi. In this role, she is accountable for delivering innovative and robust analytical methods to support the process development of HyperconTM formulations, that are fit-for-purpose and stage-appropriate. The group performs product characterization using state-of-the-art analytical techniques to assess the biochemical and biophysical properties of microparticle suspension drug products to ensure quality and stability. She is also accountable for the external technical transfer that enables the manufacturing of these drug product presentations as well as the definition of their analytical control strategy.
Prior to joining Elektrofi, Bernice worked at several major biopharmaceutical companies, including Amgen, Bristol-Myer Squibb, Shire and Biogen, mostly in analytical CMC and biologics process development. She also held a post-doctoral fellowship at Genetics Institute, Inc. (now Pfizer).
Bernice holds a Ph.D. in Analytical Chemistry from Northeastern University and a B.S. in Chemistry from the University of Delaware.
BOARD OF DIRECTORS
This team champions our purpose, our curiosity, and our ability to transform the future in biologics delivery by discovering better ways of doing things.
-
J Peter Bojo
Mr. Bojo is a Principal at TPG Life Sciences Innovation, and has been investing in healthcare at TPG since 2014. Mr. Bojo is Head of Corporate Development and a member of the board at Sling Therapeutics. He also serves on the board of Ellodi Therapeutics and has held observer roles including Engage Therapeutics (acquired by UCB), Ceribell (Nasdaq: CBLL), and Sionna (Nasdaq: SION). -
Constantine currently serves as a strategic advisor to a number of leading biotech and pharma companies, leveraging his broad experience in Corporate and Business Development.
His most recent full time role was Chief Business Officer at Albireo Pharmaceuticals, where he helped to execute the sale of the company to Ipsen Pharmaceuticals in March 2023. Prior to that, he served as Chief Business Officer of Boston Pharmaceuticals, where he executed over 20 licensing transactions in order to build the portfolio. Before joining Boston Pharmaceuticals, Constantine was Vice President and Chief Licensing Officer at Sanofi, where he was responsible for the global business development function.
He joined Sanofi following its acquisition of Genzyme in 2011 and initially assumed the role of regional head of Business Development for Sanofi's North American Pharmaceutical division. Prior to this position, he was a Vice President in Genzyme's Corporate Development group, which he joined in 2001 after 12 years at Eli Lilly in various roles.
-
Chase has extensive expertise in fluid mechanics and microsystems, propulsion technologies for nanosatellites, related laser micromachining techniques, and electrohydrodynamic theories. Prior to founding Elektrofi, he served as a Space Technology Research Fellow with National Aeronautics and Space Administration (NASA). Chase holds a Ph.D. in Philosophy and a Master of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. He earned his Bachelor of Science in Aerospace Engineering from the University of Florida.
-
Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation at MIT. He has been involved as founder, advisor or board member of over 40 companies and currently sits on the Boards of Directors of Elektrofi, Hovione AG, Innovent Biologics (1801.HK), Iterative Health, Levitronix Technologies, LayerBio, and Boyd Biomedical. In addition, he is Trustee Emeritus of Boston Ballet, Advisor Emeritus of the Boston Symphony Orchestra and Chairman & Trustee of the Leventhal Map and Education Center.
-
Andrew is a Managing Director at Marshall Wace and helps lead the XO Healthcare Innovation fund, which focuses on late-stage private investments. Before this he was a Partner on the private innovation team at Palo Alto-based Vivo Capital, where he focused on private pharmaceutical and medical device companies. Prior to Vivo, he worked at McKinsey & Company in the Silicon Valley office in their pharmaceutical and medical products practice.
Dr. Goldberg is a US board-certified physician in both Critical Care Medicine and Emergency Medicine. He received his MD from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Mayo Clinic, Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and the Washington Township Medical Foundation.
-
Arman joined BVF Partners L.P. in 2015. Before BVF, he was an investment banking analyst in the global healthcare group at Barclays, where he focused on M&A, capital raises and client advisory in the biotechnology and pharmaceutical sectors. He holds a B.A. with honors in Economics from the University of Pennsylvania.
-
Jee, Noel
Noel Jee is a Partner at Novo Holdings and invests in private companies broadly across healthcare and the life sciences. Prior to Novo Holdings, Noel was a healthcare investor with Sofinnova Investments and Illumina Ventures where he focused on therapeutics, life science tools, diagnostics, and healthcare platforms. Prior to his time as an investor, Noel was a management consultant at L.E.K. Consulting.Noel received his PhD in Chemistry and Chemical Biology from the University of California, San Francisco. Noel also holds a dual B.S. in Biochemistry and a B.S. in Neurobiology and Physiology from the University of Maryland, College Park, where he graduated with Honors.
-
Jason Norris
Jason Norris is a co-founder of Elektrofi and is focused on building transformative companies that enable people to live fuller lives. In addition to his role with Elektrofi, he also serves on the Board of Directors of Mytide Therapeutics and Lapix Therapeutics. He began his career at Wachovia Bank and also served as a Managing Director for The Bernstein Companies. Jason earned a Master of Business Administration from Massachusetts Institute of Technology Sloan School of Management and a Bachelor of Arts from University of North Carolina Chapel Hill.
